Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Egorin

Showing results (121-130 of 159) with videos related to

Pageof 16
Sort By:
Cancer Chemotherapy and Pharmacology|February 28, 2001
The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancerK P Papadopoulos, M J Egorin, M Huang, et al.
Journal of the National Cancer Institute|July 19, 1995
Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumorsM J Glantz, H Choy, C M Kearns, et al.
Cancer Research|August 15, 1991
Interaction of N,N',N''-triethylenethiophosphoramide and N,N',N''-triethylenephosphoramide with cellular DNAN A Cohen, M J Egorin, S W Snyder, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1981
Cyclophosphamide and dimethylsulfoxide in the treatment of squamous carcinoma of the lung. Therapeutic efficacy, toxicity, and pharmacokineticsJ Z Fuks, M J Egorin, J Aisner, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 miceJ L Eiseman, N D Eddington, J Leslie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumorsB A Conley, M J Egorin, N Tait, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
Approaches to optimal dosing of hexamethylene bisacetamideB A Conley, M J Egorin, V Sinibaldi, et al.
Cancer Research|January 15, 1997
Comparative molecular field analysis-based predictive model of structure-function relationships of polyamine transport inhibitors in L1210 cellsY Li, A D MacKerell, M J Egorin, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancerD C Smith, D I Jodrell, M J Egorin, et al.
Journal of Medicinal Chemistry|January 5, 1996
Synthesis and antitumor evaluation of a highly potent cytotoxic DNA cross-linking polyamine analogue, 1,12-diaziridinyl-4,9-diazadodecaneY Li, J L Eiseman, D L Sentz, et al.
Pageof 16

Showing results (121-130 of 159) with videos related to

Sort By:
Pageof 16
Cancer Chemotherapy and Pharmacology|February 28, 2001
The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancerK P Papadopoulos, M J Egorin, M Huang, et al.
Journal of the National Cancer Institute|July 19, 1995
Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumorsM J Glantz, H Choy, C M Kearns, et al.
Cancer Research|August 15, 1991
Interaction of N,N',N''-triethylenethiophosphoramide and N,N',N''-triethylenephosphoramide with cellular DNAN A Cohen, M J Egorin, S W Snyder, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1981
Cyclophosphamide and dimethylsulfoxide in the treatment of squamous carcinoma of the lung. Therapeutic efficacy, toxicity, and pharmacokineticsJ Z Fuks, M J Egorin, J Aisner, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 miceJ L Eiseman, N D Eddington, J Leslie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumorsB A Conley, M J Egorin, N Tait, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
Approaches to optimal dosing of hexamethylene bisacetamideB A Conley, M J Egorin, V Sinibaldi, et al.
Cancer Research|January 15, 1997
Comparative molecular field analysis-based predictive model of structure-function relationships of polyamine transport inhibitors in L1210 cellsY Li, A D MacKerell, M J Egorin, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancerD C Smith, D I Jodrell, M J Egorin, et al.
Journal of Medicinal Chemistry|January 5, 1996
Synthesis and antitumor evaluation of a highly potent cytotoxic DNA cross-linking polyamine analogue, 1,12-diaziridinyl-4,9-diazadodecaneY Li, J L Eiseman, D L Sentz, et al.
Pageof 16